AMALY — SHARIAH COMPLIANCE REPORT
==================================
Symbol: SRTS
Report Date: 2026-05-09
Full Report: https://amaly.io/stock/SRTS

EXECUTIVE SUMMARY
------------------
Compliance Status: COMPLIANT
Quality Rating: AAA
Description: Spero Therapeutics, Inc. (SRTS) operates in an unknown industry, focusing on biopharmaceutical development. The company demonstrates strong financial compliance with low debt levels and minimal non-compliant income, requiring only minor purification. Business activities appear permissible, with no major controversies or non-compliant segments identified. Inclusion in all major Shariah indices confirms overall compliance, making it a viable option for ethical investors.

Primary Compliance Concerns:
- Minor purification required for interest income (2.49%)

Purification Requirement: 2.49%
Index Inclusion: Included in S&P Dow Jones Shariah Indices, MSCI Islamic Indices, FTSE Shariah Indices, and Dow Jones Islamic Market (DJIM)

KEY FINANCIAL METRICS
----------------------
Debt Ratio: 0.0%
Liquidity Ratio: 25.9%
Interest Income Ratio: 2.5%
Purification Required: 2.49%

INDEX INCLUSION STATUS
-----------------------
S&P Shariah: INCLUDED
MSCI Islamic: INCLUDED
DJIM: INCLUDED
FTSE Shariah: INCLUDED
Total: 4 of 4
Last Verified: 2025-11-30

REPORTING PERIOD
-----------------
Latest Annual Report: FY 2025
Latest Quarterly Data: Q4 2025
Trend Period: FY 2020 to FY 2025
Data Retrieved: 2026-02-15T12:00:00Z

---
Full interactive report: https://amaly.io/stock/SRTS
Provided by Amaly (https://amaly.io) — Shariah Compliant Stock Screener
Disclaimer: This data is for informational purposes only and does not constitute financial or religious advice.